PV-10 (Rose Bengal) and the Cancer Immunity Cycle

Takeaways:

• Provectus collaborators like Moffitt Cancer Center in Tampa, FL and the University of Illinois at Chicago ("UIC") in Chicago, IL eventually should independently show that all of the steps in the "cancer immunity cycle," created and popularized by Chen & Mellman in 2013 [1], are present with the company's investigational drug PV-10 (Rose Bengal).

• This presence might be shown pre-clinically in different solid tumor cancer models (melanoma, colon cancer) as well as clinically in melanoma patients.

[1] Oncology Meets Immunology: The Cancer-Immunity Cycle, Chen et al., Immunity, Volume 39, Issue 1, 1-10

At the 2016 JP Morgan Healthcare Conference, both Bristol-Myers and Roche (Genentech) incorporated cancer immunity cycle visuals in their respective investors presentations. Note that Chen and Mellman are Genentech employees. Bristol-Myers's illustration is on the left, and Roche's is on the right.

Click to enlarge.

Note the differences between the two cycle designs and illustrations.

Click to enlarge.

Notable to me above are (i) Bristol-Myers' explicit mention of the tumor microenvironment, (ii) Bristol's explicit mention of NK cells, (iii) Bristol's expansion of Roche's "T cell killing" into the tumor microenvironment and T cell and NK cell activations, and below (iv) Roche's placement of Amgen's intralesional agent T-Vec (Imylgic).

Click to enlarge.

In July 2014 I created a presentation discussing the cancer immunity cycle steps and where they were present with PV-10 based on the information then available, PV-10, and the Cancer Immunity Cycle.

Click to enlarge.

Click to enlarge.

I revised in draft form the above to potentially explore cycle steps 4, 5 and 6 below with PV-10 based on Moffitt and UIC's work thus far, "Intralesional Rose Bengal in Melanoma Elicits Tumor Immunity via High Mobility Group Box 1" and "PV-10 Induces Potent Immunogenic Apoptosis in Colon Cancer Cells," respectively.

Click to enlarge.

Click to enlarge.